We are currently verifying the specificity and sensitivity of this imaging agent for ER/PR molecules, while actively pursuing various strategies to optimize the imaging system for diverse tissue types and metastatic cancers. The gene discussed is ESR1; the disease is metastatic malignant neoplasm.